Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biosimilars Begin To 'Pay Off' For Biocon

Executive Summary

Biocon rang in a strong Q3, buoyed by the momentum in its biologics business. The firm appears undeterred by suggestions that the US biosimilars market may be less attractive than initially anticipated.

You may also be interested in...

Biocon Expects ‘Successful’ US Trastuzumab Launch Despite Amgen Debut

India’s Biocon reported first-quarter net profit that soared by more than 70% and said it was confident of a “very successful” US trastuzumab launch, despite rival Amgen stealing a march by commercializing its own biosimilar first in the world’s largest drug market.

Biocon’s Biosimilar Ambitions Get A Boost With European Site Approval

Leading Indian biotech firm Biocon has got the green light for a biosimilar manufacturing facility from Europe’s drug regulator, paving the way for the company’s growing biosimilars portfolio to gain greater European market access.

Amgen Eyeing ‘Sustainable Opportunities’ In Non-US Biosimilars Markets

As it begins reporting biosimilars sales after embarking on the journey a decade ago, Amgen says it will target sizeable European countries possessing more “balanced dynamics,” such as France and Germany, for its biosimilar franchise. The California-based biotech also remains upbeat about the potential to make serious inroads in the US biosimilars market.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts